Advertisement
Advertisement
U.S. markets close in 5 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

PepGen Inc. (PEPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.80-1.03 (-8.71%)
As of 10:34AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close11.83
Open11.48
Bid10.86 x 800
Ask11.05 x 1300
Day's Range10.45 - 11.83
52 Week Range7.82 - 16.99
Volume51,049
Avg. Volume179,561
Market Cap255.225M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-42.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PEPG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PepGen Inc.
    Technical Assessment: Bearish in the Intermediate-TermMonday provided a much-needed rest for the stock market after a very large rebound last week. Following that strong week (and we've seen this before during the current decline), the "bottom-callers" are out, but not in big numbers. That's probably a good thing, as others are calling this another bear-market rally. From a technical perspective and using our own interpretation, it is far too early to call the bottom as there is just not enough of the needed evidence.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

    BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2022. “This has been a year of tremendous growth for PepGen, culminating in our recent transition to a clinical stage company and execution of a successful initial public

  • Barrons.com

    Covetrus and PepGen Stock See Action From Activist Investors

    Clayton, Dubilier & Rice disclosed a large stake in specialized-software firm Covetrus. RA Capital now has a substantial investment in biopharmaceutical firm PepGen.

  • GlobeNewswire

    PepGen Announces Pricing of Initial Public Offering

    BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of its initial public offering. The offering consists of 9,000,000 shares of common stock at an initial public offering price of $12.00 per share. The gross proceeds from the offering, before deducting underwriting discounts

Advertisement
Advertisement